SCHEMBL6790543

SCHEMBL6790543

CONC(=O)c1ccc(C(=O)O)c(NC(=O)/C=C(/C)c2ccc3ccccc3c2)c1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.71
LTB4R Q15722 1/20 0.47
KDM4E B2RXH2 2/20 0.46
DHODH Q02127 1/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
CASP3 P42574 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
ALDH1A1 P00352 2/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
ALOX12 P18054 1/20 0.41
SLC16A3 O15427 1/20 0.41
CHEK1 O14757 1/20 0.40
PIM1 P11309 1/20 0.40
MAPK8 P45983 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
NR1H4 Q96RI1 1/20 0.40
PTPN11 Q06124 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6781040 0.92 TERT (0.59) TERTLTB4RKDM4ENPC1RAB9A
SCHEMBL6785021 0.88 TERT (0.78) TERTLTB4RKDM4EDHODHNPC1
SCHEMBL6783732 0.88 TERT (0.85) TERTLTB4RKDM4EDHODHNPC1
SCHEMBL6783748 0.88 TERT (0.71) TERTLTB4RKDM4EDHODHNPC1
SCHEMBL6785371 0.87 TERT (0.73) TERTKDM4EDHODHNPC1RAB9A
SCHEMBL6786325 0.86 TERT (0.76) TERTLTB4RKDM4EDHODHNPC1
SCHEMBL6792283 0.86 TERT (0.76) TERTLTB4RKDM4EDHODHNPC1
SCHEMBL6781639 0.86 TERT (0.66) TERTLTB4RKDM4ENR1H4
SCHEMBL6791288 0.86 TERT (0.62) TERTLTB4RKDM4E
SCHEMBL6782070 0.85 TERT (0.71) TERTLTB4RKDM4EDHODHNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885LTB4R 3433/4885KDM4E 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.